In October, Express Scripts announced that it would add Viatris’ SEMGLEE (insulin glargine-yfgn) injection as a preferred therapy on its formulary beginning in January 2022. Back in July, the FDA approved SEMGLEE as the first biosimilar insulin to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. According to the release, SEMGLEE is both biosimilar to, and interchangeable with, its reference product LANTUS (insulin glargine), a long-acting insulin analog. Express Scripts estimates cost savings of $20 million in 2022 by preferring SEMGLEE injection on its National Preferred Formulary, which includes more than 28 million lives.